Outpost Medicine rakes in $20 mln

Indianapolis and London-based Outpost Medicine, a biopharmaceutical company focused on treating urologic and gastrointestinal disorders, has raised $20 million in funding. The investors included Takeda Ventures, Frazier Healthcare Partners, Novo Holdings A/S, Vivo Capital and Adams Street Partners. Also, the company has appointed Scott Byrd as president and CEO, succeeding David Socks, interim CEO, co-founder of Outpost, and venture partner with Frazier Healthcare Partners. Socks will remain on the board of directors.

ManagersNorth AmericaUSHealthcareBriefs